Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Knoll Takeover Value Hinges On Outlook For D2E7 Rheumatoid Arthritis Agent

  • News

Executive Summary

Knoll's valuation as a potential acquisition target appears to depend on assessments of the outlook for the anti-TNF monoclonal antibody D2E7.

You may also be interested in...



DuPont Oral TNF Inhibitor For Arthritis, Sustiva Successor Are In Phase II

DuPont Pharmaceuticals expects to file an NDA for an orally dosed TNF inhibitor in 2004, the company told analysts April 11.

DuPont Oral TNF Inhibitor For Arthritis, Sustiva Successor Are In Phase II

DuPont Pharmaceuticals expects to file an NDA for an orally dosed TNF inhibitor in 2004, the company told analysts April 11.

Genelabs/Watson Aslera Lupus Deal Includes $30.5 Mil. In Up-Front Payments

Watson Pharmaceuticals is investing $30.5 mil. up front to help Genelabs Technologies bring its systemic lupus erythematosus treatment Aslera (prasterone) to market, the companies jointly announced Nov. 13.

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS036923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By